Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for
Vivos is buying a piece of another company called SOD Sciences. They are paying with stock and getting access to a test that finds health problems early.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.